Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;47(5):669-73.
doi: 10.1016/j.amepre.2014.07.007. Epub 2014 Sep 19.

A public health approach to the prevention of inhibitors in hemophilia

J Michael Soucie  1 , Connie H Miller  2 , Fiona M Kelly  2 , Meredith Oakley  2 , Deborah L Brown  3 , Phillip Kucab  4
Affiliations

A public health approach to the prevention of inhibitors in hemophilia

J Michael Soucie et al. Am J Prev Med. 2014 Nov.

Abstract

The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Soucie JM, Evatt B, Jackson D. The occurrence of hemophilia in the U. S Am J Hematol. 1998;59(4):288–94. - PubMed
    1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–35. - PubMed
    1. Soucie JM, Miller CH, Kelly FM, et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the U. S Haemophilia. 2014;20(2):230–7. - PMC - PubMed
    1. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7(2):198–206. - PubMed
    1. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the U.S 2008. Haemophilia. 2012;18(2):268–75. - PMC - PubMed